Education
About Us
Working with TipRanks
Follow Us
BioRestorative Therapies (BRTX)
NASDAQ:BRTX
Earnings Data
Report Date
May 20, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.33Last Year’s EPS
-0.33Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 27, 2025
|% Change Since: -2.73%
|Next Earnings Date:May 20, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant revenue growth, improved financial performance, strong cash reserves, and promising clinical trial developments, including FDA Fast Track designation and expansion into new indications. However, ongoing financial losses and uncertain outcomes in potential licensing agreements were noted as challenges.Company Guidance
During the BioRestorative Therapies 2024 Results Conference Call, key financial and operational metrics were shared. The company reported a 175% year-over-year revenue increase to $401,000 for the fiscal year ending December 31, 2024. They achieved a 24% improvement in loss from operations, reducing it to $11.6 million from $15.2 million in 2023. The net loss for 2024 was $9 million, or $1.16 per share, compared to $10.4 million, or $2.47 per share, in the previous year, marking a 14% improvement. Cash used in operating activities was $8.2 million, and the company ended the year with $10.7 million in cash, cash equivalents, and marketable securities, with no outstanding debt. The company also highlighted progress in their clinical programs, noting that their lead candidate BRTX-100 received FDA Fast Track designation and IND clearance for a Phase 2 trial targeting chronic cervical discogenic pain.Record Revenue Growth
BioRestorative experienced a revenue growth of 175% year-over-year, reaching $401,000 for the 12-month period ending December 31, 2024.
Improved Financial Performance
The company's loss from operations was reduced by 24% from $15.2 million in 2023 to $11.6 million in 2024. Net loss also improved by 14% from $10.4 million in 2023 to $9 million in 2024.
Strong Financial Position
BioRestorative ended the year with $10.7 million in cash, cash equivalents, and marketable securities, with no outstanding debt.
Positive Clinical Trial Developments
In the ongoing Phase 2 trial for BRTX-100, no serious adverse events or dose-limiting toxicity were reported. Preliminary data indicated positive trends in treating chronic lumbar disc disease.
FDA Fast Track Designation
BRTX-100 received Fast Track designation from the FDA for chronic lumbar disc disease, facilitating development and expediting review.
Expansion into New Clinical Trial
The FDA cleared BioRestorative's IND application for a Phase 2 clinical trial targeting chronic cervical discogenic pain, making BRTX-100 the first stem cell product candidate cleared for this setting.
Innovative Preclinical Program
The ThermoStem program showed promise in preclinical studies, with significant reductions in weight and blood glucose levels in mice models.
---
BRTX Earnings History
Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release | Slides | Play Transcript |
|---|---|---|---|---|---|---|---|
| May 20, 2025 | 2025 (Q1) | -0.33 | ― | ― | ― | ||
| Mar 27, 2025 | 2024 (Q4) | -0.6 | 66.67% (+0.40) | ― | |||
| Nov 12, 2024 | 2024 (Q3) | -0.64 | 79.69% (+0.51) | ― | |||
| Aug 13, 2024 | 2024 (Q2) | -0.77 | 35.06% (+0.27) | ― | ― | ||
| May 14, 2024 | 2024 (Q1) | -1.53 | 78.43% (+1.20) | ― | ― | ||
| May 15, 2018 | 2018 (Q1) | -2240 | 30.36% (+680.00) | ― | ― |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
BRTX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 27, 2025 | $1.83 | $1.81 | -1.09% |
| Nov 12, 2024 | $1.64 | $1.54 | -6.10% |
| Aug 13, 2024 | $1.41 | $1.40 | -0.71% |
| May 14, 2024 | $1.36 | $1.37 | +0.74% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does BioRestorative Therapies (BRTX) report earnings?
BioRestorative Therapies (BRTX) is schdueled to report earning on May 20, 2025, TBA Not Confirmed.
What is BioRestorative Therapies (BRTX) earnings time?
BioRestorative Therapies (BRTX) earnings time is at May 20, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BRTX EPS forecast?
BRTX EPS forecast for the fiscal quarter 2025 (Q1) is -0.33.
---